Neo Ivy Capital Management Makes New $1.83 Million Investment in Illumina, Inc. $ILMN

Neo Ivy Capital Management bought a new stake in Illumina, Inc. (NASDAQ:ILMN) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 19,238 shares of the life sciences company’s stock, valued at approximately $1,827,000.

Other institutional investors have also modified their holdings of the company. Parkside Financial Bank & Trust raised its stake in shares of Illumina by 65.7% during the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 115 shares during the last quarter. Quent Capital LLC purchased a new position in Illumina in the 3rd quarter valued at $29,000. Aster Capital Management DIFC Ltd acquired a new position in Illumina in the 3rd quarter valued at $33,000. Mather Group LLC. acquired a new position in Illumina in the 3rd quarter valued at $46,000. Finally, Evelyn Partners Investment Management LLP raised its position in Illumina by 4,927.3% during the 2nd quarter. Evelyn Partners Investment Management LLP now owns 553 shares of the life sciences company’s stock worth $49,000 after buying an additional 542 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insider Activity at Illumina

In related news, SVP Patricia Leckman sold 2,370 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the transaction, the senior vice president directly owned 16,321 shares of the company’s stock, valued at $1,896,173.78. This trade represents a 12.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Scott M. Davies sold 323 shares of Illumina stock in a transaction on Friday, December 12th. The stock was sold at an average price of $136.09, for a total value of $43,957.07. Following the transaction, the insider directly owned 17,887 shares of the company’s stock, valued at approximately $2,434,241.83. This represents a 1.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 2.60% of the company’s stock.

Illumina Stock Performance

NASDAQ:ILMN opened at $124.62 on Friday. The firm’s fifty day simple moving average is $134.37 and its 200-day simple moving average is $119.12. The company has a quick ratio of 1.72, a current ratio of 2.08 and a debt-to-equity ratio of 0.55. The stock has a market cap of $19.05 billion, a PE ratio of 22.87, a price-to-earnings-growth ratio of 2.45 and a beta of 1.45. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $155.53.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.26 by $0.09. The firm had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.10 billion. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter last year, the business earned $0.95 earnings per share. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ILMN has been the subject of several recent analyst reports. UBS Group restated a “neutral” rating and issued a $135.00 target price on shares of Illumina in a research note on Friday, February 6th. Barclays increased their price target on shares of Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a report on Monday, December 15th. Zacks Research downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 31st. JPMorgan Chase & Co. lowered their price objective on Illumina from $130.00 to $120.00 and set a “neutral” rating on the stock in a report on Friday, February 6th. Finally, Robert W. Baird set a $137.00 target price on Illumina in a research report on Friday, February 6th. Six investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Illumina currently has a consensus rating of “Hold” and an average target price of $129.69.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.